Xeris Pharmaceuticals Inc. (XERS) Tops Q1 EPS by 4c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
May 13, 2021 7:00 AM EDTGvoke® quarterly net sales of $8.1 million
Record quarterly Gvoke prescription volume
Strong cash position of $136.0 million
Conference call and webcast today at 8:30 a.m. ET
CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced financial results for the first quarter 2021 and recent highlights.
We are very pleased with our steady, consistently growing financial performance... More
